PolyPid Stock (NASDAQ:PYPD)
Previous Close
$3.31
52W Range
$2.95 - $9.20
50D Avg
$3.47
200D Avg
$4.17
Market Cap
$24.12M
Avg Vol (3M)
$6.72K
Beta
1.32
Div Yield
-
PYPD Company Profile
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
PYPD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CUE | Cue Biopharma, Inc. |
| BWV | Onconetix, Inc. |
| VRPX | Virpax Pharmaceuticals, Inc. |
| KPRX | Kiora Pharmaceuticals, Inc. |
| REVB | Revelation Biosciences, Inc. |
| LABP | Landos Biopharma, Inc. |
| HILS | Tharimmune, Inc. |
| VACC | Barinthus Biotherapeutics plc |
| VRAX | Virax Biolabs Group Limited |
| EFTR | eFFECTOR Therapeutics, Inc. |
| INAB | IN8bio, Inc. |
| CYTO | Altamira Therapeutics Ltd. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| PYXS | Pyxis Oncology, Inc. |
| ANIX | Anixa Biosciences, Inc. |
| INMB | INmune Bio, Inc. |
| ZURA | Zura Bio Limited |
| ELEV | Elevation Oncology, Inc. |